期刊
CURRENT OPINION IN PHARMACOLOGY
卷 47, 期 -, 页码 110-118出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2019.03.001
关键词
-
资金
- Agence Nationale de la Recherche [ANR-18-CE92-0046]
- Institut National Du Cancer [INCa 2015-137]
- Deutsche Forschungsgcmeinschaft [310/11, 310/13, SFB1192-B5, SFB1328-A10]
- Deutsche Akadcmische Austauschdienst
- Claussen-Simon-Stiftung
- European Cooperation in Science and Technology COST Action IONCHAN-IMMUNRESPON [BM1406]
Targeting the P2X7 ion channel, a danger sensor for extracellular nucleotides, improves outcomes in models of inflammation, cancer, and brain-diseases. Antibodies and nanobodies have been developed that antagonize or potentiate gating of P2X7. Their potential advantages over small-molecule drugs include high specificity, lower off-target effects, and tunable in vivo half-life. Genetic fusion of P2X7-specific biologics to binding modules may enable targeting of specific cell subsets. Besides directly modulating P2X7 function, antibodies can also initiate specific depletion of P2X7-expressing cells. Adeno-associated viral vectors (AAV) can be used to express P2X7-specific antibodies in vivo to achieve long-lasting biological effects. Furthermore, if successfully targeted to P2X7-expressing cells, AAVs may enable modulation of the function of P2X7-expressing immune cells via encoded transgenic RNA or proteins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据